The blinded, multicenter, prospective, randomized 60-patient study’s objective is to establish non-inferiority of the Z-Lig to allograft .

Aperion said the results will be used to support regulatory commercialization approvals of the Z-Lig ACLR device in select markets outside of the US.

Aperion’s Z-Lig is a proprietary immunochemically modified porcine tissue-based, sterile device designed for implantation to reconstruct a ruptured anterior cruciate ligament (ACL).